How TABRECTA May Help

TABRECTA (capmatinib) tablets

Proven clinical trial results

In a clinical trial, TABRECTA was studied in 2 different groups of people with MET exon 14 skipping (METex14): those taking TABRECTA as their first treatment and those previously treated before taking TABRECTA.

  • The overall response rate measures the size or number of tumors people have. This number includes:
    • people whose tumors became smaller or fewer in number (which is called a partial response), and
    • people whose tumors disappeared completely (which is called a complete response). A complete response is not the same thing as a cure.
  • Duration of response is the length of time that a tumor continues to respond to treatment without the cancer growing or spreading.
For people taking TABRECTA as their first treatment: Proven to shrink tumors in 67.9% of people. TABRECTA worked for over 1 year (12.6 months).

For people taking it as their first treatment, TABRECTA is proven to shrink tumors. Among those previously untreated, 68% of 28 people achieved a response with TABRECTA. Of these responders, 4% had a complete response and 64% had a partial response. The median (or midpoint) duration of response for people who were untreated before taking TABRECTA was 12.6 months. This means that half of the people who responded to treatment continued to respond for longer than 12.6 months and half responded for less than 12.6 months.

 

For people previously treated before taking TABRECTA: Proven to shrink tumors in 40.6% of people. Amount of time TABRECTA worked was 9.7 months.

For people previously treated, TABRECTA is proven to shrink tumors. Among those previously treated, 41% of 69 people achieved a response with TABRECTA. Of these responders, 0% had a complete response and 41% had a partial response. The median (or midpoint) duration of response for people who were previously treated before taking TABRECTA was 9.7 months. This means that half of the people who responded to treatment continued to respond for longer than 9.7 months and half responded for less than 9.7 months.